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Running title: 
Functions of complement C3-derived ligands 
 
 
Summary 
The complement system is a major component of immune defence. Activation of the 
complement cascade by foreign substances and altered self-structures may lead to the 
elimination of the activating agent, and during the enzymatic cascade several biologically 
active fragments are generated. Most immune regulatory effects of complement are mediated 
by the activation products of C3, the central component. The indispensable role of C3 in 
opsonic phagocytosis as well as in the regulation of humoral immune response is known for 
long, while the involvement of complement in T cell biology have been revealed in the past 
few years. In this review we discuss the immune modulatory functions of C3-derived 
fragments focusing on their role in processes which have not been summarized so far. The 
importance of locally synthesized complement will receive special emphasis, since several 
immunological processes take place in tissues, where hepatocyte-derived complement 
components might not be available at high concentrations. We also aim to call the attention to 
important differences between human and mouse systems regarding C3-mediated processes.  
 
Keywords:  
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Introduction  
 
The complement system is one of the most versatile constituents of the immune system. This 
network of more than 30 soluble and cell surface proteins plays an important role in innate 
defence as well as instructing and regulating adaptive responses. Complement activation can 
be triggered by a wide variety of substances, including immune complexes, foreign structures, 
altered host cells and apoptotic bodies. The cascade involves sequential activation of 
complement components, leading to inflammation, clearance of pathogenic microorganisms 
and apoptotic cells, thus contributes to maintaining host homeostasis. In the course of 
activation several biologically active fragments are generated, which exert immune regulatory 
functions via binding to various complement receptors and regulators expressed by a wide 
variety of cell types.  
Activation of the complement cascade can occur via three pathways: the classical, 
lectin-dependent and alternative route (Fig.1). The classical pathway is set off by activation of 
the C1-complex, which is initiated by binding of its C1q subunit to the Ig Fc-region in 
antigen-antibody complexes, to apoptotic cells and to C reactive protein. The lectin pathway 
is triggered by Mannan Binding Lectin and ficolins, the pattern recognition molecules, which 
recognize carbohydrates on microbial surfaces. The alternative route is initiated by C3(H2O), 
which is deposited on activator surfaces as a result of spontaneous and slow hydrolysis of C3 
(“tick over mechanism”) and serves as an amplification loop for the other two activation 
routes. Independent of the initial trigger however, all these pathways lead to the formation of 
an enzymatic complex which cleaves C3, the central complement component. 
In this review we focus on the immune modulatory role of C3-derived fragments, with 
particular attention to functions which have not been summarized so far. We emphasize 
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studies in human systems and aim to highlight similarities and important differences between 
the human and mouse systems. 
 
 
Activation of component C3, generation of biologically active C3-fragments  
 
Component C3 is the most abundant complement protein in serum and body fluids. It is 
present in the circulation in a concentration of 1.2–1.5 mg/ml, which is comparable to the 
amount of IgG3 in human serum. The primary source of serum C3 is the liver, however its 
local production by several cell types – including macrophages, dendritic cells, lymphocytes 
and epithelial cells – in various tissues is also known to play an important role in the initiation 
and regulation of adaptive immune responses (1-3).  
The first cleavage products of the central component C3 are C3a and C3b (Fig.1). The 
small soluble C3a peptide binds to guanine nucleotide binding protein (G-protein) coupled 
C3a receptors, which are widely distributed in peripheral tissues and the central nervous 
system, suggesting that this peptide plays a diverse and more prominent role in various 
biological functions than earlier thought. The anaphylatoxic effect of C3a is known for long, 
however its role in adaptive immunity has been revealed only in the past few years. These 
results have been extensively reviewed recently elsewhere (4, 5). 
Upon activation into fragment C3b the molecule undergoes marked conformational 
changes exposing binding sites for interaction with other proteins (6). C3b in its nascent state 
has the capacity to bind covalently to C3b-acceptor (C3bA) sites via its newly exposed, short-
lived thioester group (7). C3bAs are hydroxyl and amine groups of proteins or carbohydrates, 
which are present on the activator surface, including cell membranes and various foreign 
structures. It is known for long that covalently fixed C3b is not only a subunit of additional 
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C3-convertases, but serves as a regulator of the complement cascade and is the major ligand 
to complement receptor type 1 (CR1, CD35). Activator-bound C3b can be further processed 
by factor I to generate inactivated C3b (iC3b) and C3d(g), which remain covalently attached 
to C3bAs and are ready to interact with complement receptors CR3, CR4, CRIg and CR2, 
respectively (Fig.1). The phagocytic complement receptor of the immunoglobulin superfamily 
(CRIg), which binds C3b and iC3b has also been described on tissue resident macrophages 
(8). 
 
 
Covalent binding of nascent C3b to C3bAs  
 
As alluded above, when C3 is activated by C3-convertases or trypsin-like serine proteases, the 
internal thioester is exposed and approximately 10% of the generated nascent C3b molecules 
form ester or amide bonds with proteins and carbohydrates during their short half-life. The 
covalent binding reaction has been thoroughly studied employing red blood cells (RBCs) (7), 
Sepharose-trypsin (9) and glycine and glycerol as representative small molecules with amino 
and hydroxyl groups (10). 
The phenomenon of immune adherence has been described long time ago by Nelson, 
who demonstrated that complement-opsonized microorganisms adhere to human erythrocytes 
(11). Later Fearon demonstrated that binding and clearance of C3-opsonized particulate 
antigens and immune complexes (ICs) is mediated by CR1 present on human red blood cells, 
and identified this complement receptor on other human cell types, including monocytes, B 
cells and neutrophil granulocytes (12).  
It is known for long, that the covalent fixation of C3 is necessary for opsonisation of 
pathogens and foreign structures, which enhance their uptake by phagocytes via CR1, CR3 
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and CR4 receptors. Several molecules have been identified as C3bAs in various pathogens, 
such as major outer membrane protein from Legionella pneumophila (13), lipophosphoglycan 
from Leishmania major (14), glycolipid-1 from Mycobacterium leprae (15), and heparin-
binding hemagglutinin from Mycobacterium tuberculosis (16). In the membrane of RBCs 
glycophorin was identified as the main C3bA molecule (17). As will be detailed in the next 
section, the covalent attachment of C3b to nucleated cells has been demonstrated in several 
studies, but so far only CR2 on human B lymphocytes has been identified as a C3bA site (18). 
 
C3b deposition on nucleated cells  
 
Autologous cells normally are protected by the regulatory molecules from C3b-fixation which 
may lead to complement dependent lysis. Nevertheless, deposition of C3b onto the surface of 
nucleated cells can occur not only in pathologic conditions, like in the case of malignantly 
transformed cells (19, 20) and virus infected cells (21, 22), but also in physiological 
conditions (23, 24) and in the case of the monocytic human cell line U937 (25). Furthermore 
Matsumoto and Seya demonstrated C3 deposition and homotypic cell adhesion in the case of 
P39, a human myeloid cell line (26). In mouse studies di Renzo et al. found that Lewis lung 
carcinoma cells - which do not express complement receptors - fix C3 covalently to the cell 
membrane, and after internalization of the acceptor-bound C3b the growth of these cells is 
elevated (27). 
Despite the fact that hydroxyl or amine groups of proteins and carbohydrates are 
available on the cell membrane for the covalent interaction, nascent C3b does not react 
randomly or non-specifically (28). This is confirmed by the study of Marquart et al. and our 
findings, which demonstrate that normal human peripheral blood mononuclear cells (PBMCs) 
are heterogeneous from this aspect and mainly B cells, macrophages and dendritic cells (DCs) 
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– i.e. cells which also may serve as antigen presenting cells (APCs) bind C3b covalently (23, 
24, 29-36). T cells seem to acquire this capability only after activation (37, 38). In mice 
macrophages and B cells, but not T lymphocytes were found to fix C3b covalently (34). These 
data suggest that both the availability of C3bA sites and the limited proteolysis of deposited 
C3-fragments on the cell membranes are regulated by so far unravelled factors and 
mechanisms.  
In the case of human B cells CR2 has been identified as the main C3bA, and it has 
been proven that CR2 is involved in the formation of the alternative pathway convertase that 
generates further nascent C3b fragments for covalent fixation (18, 30). However, CR2 
negative human monocytes and granulocytes (24), human monocyte derived macrophages 
(MDMs) (31), human monocyte derived dendritic cells (MDCs) (36), carcinoma cells (27) 
and B cells derived from CR1/2 knock out (KO) mice (34) also have the capacity to fix C3b 
covalently. Therefore additional, so far unidentified cell membrane molecules may also serve 
as C3bAs. In the extract of serum or C3-treated cells high molecular weight complexes 
containing C3-fragments had been detected by several groups, but the C3b-acceptor 
molecules could not be identified (26, 27, 29, 39). Therefore the intriguing question still needs 
to be answered: which cell membrane molecules serve as C3bAs on nucleated cells which do 
not express CR2?  
Nevertheless, as will be discussed in the next sections, various immunomodulatory 
functions of C3bA-bound C3-fragments have been described in the case of several cell types.  
 
 
Immunomodulatory function of C3bA bound fragments 
 
C3-fragments as bivalent ligands enhance cytotoxic reactions  
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Potentiation of antibody dependent cellular cytotoxicity (ADCC) by target cell-bound C3b has 
been shown using human peripheral lymphocytes and C3b-coated chicken erythrocytes by 
Ghebrehiwet et al. (40), who demonstrated that at low anti-target antibody concentrations 
erythrocyte bound C3b significantly increased target cell lysis. The inverse situation has also 
been described; namely, effector cell-bound C3b was found to elevate ADCC, too. In these 
experiments concanavalin A stimulated human lymphocytes were demonstrated to cleave C3 
by their cell membrane proteases and fix C3-fragments covalently, which enhanced the lysis 
of antibody-sensitized CR1-positive erythrocytes (37). These results clearly show that C3b, as 
a bivalent ligand, amplifies the cytotoxic reaction by improving the contact between the 
effector and target cells, regardless of the orientation of the complement fragment. This was 
strengthened by the studies of Ramos et al. using cells of Epstein-Barr virus (EBV)-positive 
Burkitt lymphoma lines which activate and bind C3 (22). They demonstrated that these 
lymphoblasts possess increased sensitivity to lymphocyte mediated lysis during complement 
dependent cellular cytotoxicity (CDCC). 
 
C3-fragments fixed to APCs and exosomes enhance T cell responses 
 
C3-derived fragments C3a, C3b and iC3b have been shown to affect T cell functions directly 
or via APCs. Modulation of T cell proliferation, differentiation and survival by the 
anaphylatoxic peptides C3a and C5a and their receptors has been extensively studied and 
reviewed recently (41-44).  
Here we focus on the T cell modulatory effect of the larger C3-derived fragments; C3b 
and iC3b. The role of cell bound C3b in the process of antigen presentation was revealed by 
demonstrating that A20 murine cells of the B lymphoblastoid cell line and concanavalin A-
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elicited peritoneal macrophages, which serve as APCs, are able to fix C3-fragments 
covalently when incubated in autologous serum. These C3b-bearing cells were shown to 
promote the proliferation of antigen-specific T cells, particularly at suboptimal antigen doses. 
It has been proven that CR1/CR2 is expressed on the responding, activated T cells, which 
interacts with C3b deposited to C3bAs on the surface of APCs, thus strengthening the contact 
between the two cell types (32) (Fig.2). The possible in vivo significance of this bridge-
forming capacity of C3b was demonstrated by using APCs derived from mice injected with 
gamma-inulin, a known adjuvant which activates the alternative pathway. It was found that 
C3 split-products are deposited on the surface of macrophages in vivo, which elevate the 
response of antigen specific T cells 2.5-fold compared with APCs of untreated animals (33). 
The mechanism proposed might apply in all conditions when complement activating 
antigens/adjuvants are used.  
In addition to C3b fixed to APCs, exosomes released by these cells were also shown to 
influence T cell responses. Earlier Raposo et al. demonstrated that activated APCs release 
exosomes containing major histocompatibility complex (MHC), co-stimulatory and adhesion 
molecules, which mediate antigen presentation to T cells (45). These studies were extended 
and exosomes secreted by C3-fragment bearing murine B lymphocytes and macrophages were 
investigated (34). It was found that these vesicles contain C3-fragments and significantly 
enhance specific T cell responses at suboptimal antigen doses (Fig.2). This finding might 
have an important relevance in vivo, since both virus-infected and tumor cells are known to 
fix C3b (19-22). Therefore, C3b-coated exosomes released by these cells might contribute to 
the immune response in pathologic conditions, particularly when the antigen stimulus is low. 
Dendritic cells (DCs) – similarly to macrophages - are known to produce most of the 
complement components, including C3, furthermore several functions of DCs were shown to 
be influenced by complement receptors CR3 and CR4 (43, 46, 47). Using C3 KO animals 
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Zhou et al. proved the importance of this protein in antigen presentation (48). Importantly, the 
role of C3 in the differentiation of DCs has been clearly demonstrated in a C3-deficient case 
by Ghannam et al. (49).  
It is known from the studies of several groups that ligation of CR3 and CR4 inhibits 
DC maturation (50-53). To obtain a deeper insight into the role of complement in DC 
functions, we focused our attention on the phenotypical and functional changes induced by 
acceptor-bound C3b. Consistent with previous studies carried out with murine cells, human 
MDCs were able to fix C3b covalently (36). When native C3 or fresh human serum was 
added to MDCs allowing the covalent binding of C3b, a markedly increased expression of 
MHCII, CD83 and CD86 molecules, and a significantly enhanced secretion of TNF-α, IL-6 
and IL-8 cytokines were detected, while C3 inactivated by the nucleophilic methylamine had 
no effect. These results are in agreement with data of Ghannam et al. who reported that in a 
primary human C3-deficient patient DC maturation was lacking (49). They also found that the 
total number of MDCs was significantly lower in this patient than in healthy individuals. It 
has to be noted that the phenotype of MDCs stimulated by covalently bound C3-fragments 
was markedly different from LPS matured MDCs, proving that a “danger signal” and a 
physiological stimulus direct DC maturation into different ways (36). A further important 
functional consequence of C3b-fixation was the elevated capacity of MDCs to stimulate 
allogeneic T cells. The possible involvement of CR3 in fixing C3-fragments was excluded by 
using CD11b RNA silenced cells. Modelling an in vivo occurring situation in secondary 
lymphoid organs, activated macrophages and MDCs were cocultured, which resulted in 
fixation of sufficient amounts of C3-fragments on the APCs to elevate T cell activation. 
Regarding the mechanism of this process we propose that DC-bound C3b interacts with CR1 
expressed on T lymphocytes and functions as an adhesion molecule between DCs and T cells 
(Fig.3). In these experiments C3 production by MDCs could not be detected, therefore these 
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APCs were most probably “opsonized” by macrophage-derived C3-fragments. These results 
broaden the concept of “local opsonisation” of microbes occurring in the close vicinity of 
activated, C3 producing macrophages (54), and reveal a novel way to enhance the interplay 
between macrophages, DCs and T lymphocytes (36). It should be noted, that a substantial 
portion of the covalently fixed C3-fragments were internalized by MDCs in 30 minutes in our 
experiments (36). Although the possible involvement of this intracellular C3 in promoting T 
cell response was not investigated, it might have a role described recently by Botto et al. (55). 
According to their studies C3 bound to dying cells can direct the cargo in APCs and influence 
T cell response to antigens.  
Considering that DCs and macrophages are present in tissues at strategically critical 
sites where hepatocyte-derived complement is not available, C3 produced locally by these 
cells might strongly influence the acquired immune response.  
 
 
Human T cell derived iC3b deposited on the cell membrane promotes autologous T 
cell proliferation  
 
Production of the anaphylatoxic peptides C3a and C5a during cognate interactions between T 
cells and APCs has been thoroughly investigated, and their role in T cell biology was 
demonstrated over the past years in excellent papers (44, 56-58). Regarding complement 
synthesis by human T cells and the effect of the larger C3-fragments on T cell functions 
however, data are much sparse and controversial. Earlier Pantazis et al. showed that virus 
infected T cell lines produce C3 (59) and recently Cardone et al. demonstrated C3b deposition 
on activated CD4+ T cells (60). Studying human T cells derived from the blood and tonsil it 
was demonstrated recently that after stimulation with anti-CD3 these cells produce C3, and 
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iC3b fragments become deposited on the cell surface (38). T cell bound iC3b was shown to 
act as a costimulatory molecule by interacting with CR3 and probably CR4 receptors 
expressed by MDCs, and significantly enhanced autologous T cell proliferation.  
 
 
CR1 (CD35) and CR2 (CD21)  
 
As mentioned earlier, covalently fixed C3b and its proteolytic cleavage fragments iC3b and 
C3d(g) serve as ligands to complement receptors CR1 (CD35), CR2 (CD21), CRIg and 
members of the β2-integrin family: CR3 (CD11b/CD18) and CR4 (CD11c/CD18), 
respectively (Fig.1). These receptors are widely distributed on different cell types and exert a 
great variety of biological functions. Although the overall structure of these receptors is 
identical or very similar in men and mice, it has to be emphasized that regarding their tissue 
distribution and function there are significant differences between these two species (Table 1). 
In mice both CR1 and CR2 are encoded by the same gene (Cr2), and alternative 
splicing gives rise to the two protein products which have identical functions (61). Mouse 
CR1 comprises 21 Short Consensus Repeats (SCRs) while mouse CR2 is identical to this 
protein, except that it lacks the first 6 SCRs. In humans two separate genes (Cr1 and Cr2) 
encode for CR1 and CR2, producing two different cell membrane proteins with distinct tissue 
distribution and functions (62) (Table 1, Fig.4).  
In humans CR1 is expressed by polymorphonuclear (PMN) leukocytes, monocytes, 
macrophages, B and T cells, follicular dendritic cells (FDCs) and erythrocytes, while in mice 
CR1/2 expression is restricted to B cells and FDCs (63, 64) and appears on activated T cells 
(32). Human CR1 is an approximately 200 kDa single chain transmembrane glycoprotein with 
a short cytoplasmic tail. In the most common human allotype the extracellular portion of the 
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molecule is composed of 30 SCRs. CR1 binds activated fragments of C3 and C4, such as C3b 
and C4b and with lower affinity, iC3b. It belongs to the complement regulators and possesses 
decay accelerating activity for the C3/C5-convertases of the classical and alternative 
pathways. Additionally, it serves as a cofactor for Factor I-mediated cleavage of C3b, thus 
blocks further activation of the complement cascade. Its further important activities include 
phagocytosis by macrophages and granulocytes, transport of C3-opsonized immune 
complexes by erythrocytes and maintenance of immunological memory by FDCs (reviewed 
in: (65). Recently CR1 has been demonstrated to bind EBV on human B cells (66). On T cells 
inhibition of CR1-mediated functions were demonstrated by Wagner et al. (67) and CR1 was 
found to be involved in the generation of Treg cells (68). As will be discussed later, CR1 
expressed by human B lymphocytes exerts a strong inhibitory effect (69, 70) (Table 1). 
CR2 is a surface glycoprotein expressed on B cells, FDCs, epithelial cells and a subset 
of T cells (63, 71). In both species, CR2 appears either as a subunit of the CD19/CD21/CD81 
complex, or associated with CR1 (26, 72). In the trimolecular complex CR2 functions as the 
ligand binding unit whereas CD19 mediates signal transduction (73). A further functional link 
between human CR1 and CR2 might be provided by the co-factor activity of CR1, which in 
the presence of Factor I facilitates the production of C3d, the ligand for CR2. Although CR1 
and CR2 can be found associated on normal human B cells, each receptor can cap 
independently (74).  
Besides promoting antigen (Ag)-induced B cell activation, CR2 was also proven to 
rescue peripheral B cells from apoptosis and to enhance Ag processing and presentation of 
C3d-bound particles (75). In addition, FDC-expressed CR2 is essential for trapping C3 
fragment-tagged Ags – similarly to CR1 – thereby contributes to the maintenance of 
immunological memory and development of long-term B cell responses. CR2 is the receptor 
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for EBV on human B cells (76), and has been demonstrated to serve also as the receptor for 
CD23 (77).  
 
 
 Murine CR1and CR2 enhances humoral immune response 
 
The immunomodulatory role of CR1 and CR2 on B lymphocytes was mainly studied using 
animal systems. In 1974 Pepys found an impaired humoral immune response to both T cell 
dependent and T cell independent antigens in mice deficient in C3 (78). Later it has been 
shown that mice lacking CR1 and CR2, the receptors which interact with the C3-derived 
fragments, do not develop antibody response (79, 80). In the same year the adjuvant effect of 
C3d was proven by Dempsey et al. Employing the recombinant model antigen, hen egg 
lysozyme (HEL) coupled to two or three copies of C3d was 1000–10.000-fold more 
immunogenic than HEL alone (81). It is important to note however, that the construct 
containing only one copy of C3d was tolerogenic in vivo. This might be explained by earlier 
findings which demonstrate that soluble C3d controls the growth of activated B cells (82) in 
contrast to polyvalent C3-fragments (83).  
 As a B cell receptor (BCR) independent function, targeting antigen to murine CR1 and 
CR2 either by single chain antibody fragments or by chemically engineered whole antibodies 
was shown to enhance the efficiency of antigen presentation (84, 85). Targeting of antigen-
bound C3b and C4b and its role in antigen presentation were proven in human systems as 
well, using EBV-transformed lymphoblastoid cells (86, 87). The role of CR1 and CR2 in 
murine B cell differentiation and function has been extensively reviewed elsewhere (88-90).  
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Human CR1 and CR2 exert opposing functions  
 
As mentioned earlier there are significant differences between the expression and function of 
human and murine CR1 and CR2, therefore results obtained in mouse systems should be 
translated to humans with great caution. In the following section the immunomodulatory role 
of complement receptors expressed by human B cells will be discussed with particular 
attention to CR1, which down-modulates B cell responses in contrast to the activatory CR2. 
In contrast to mouse B cells, where ligation of BCR to CR1 and CR2 or clustering 
complement receptors by multimeric ligands strongly elevates antibody production, the 
response of human B cells to ligation of CR1 and CR2 is much more diverse (Fig.4). 
Regarding the role of CR2 on human B cells results are in line with data on mouse B cells. 
Namely, depending on whether C3d, the natural ligand is presented in soluble or crosslinked 
form, CR2 can mediate either negative or positive signals (91-93). Antibody to CR2 was 
shown to induce proliferation of human B cells in the presence of T cells (94, 95) and ligand 
binding to CD21 was found to augment BCR induced activation via a selective, c-fos 
dependent signaling pathway (96). Nevertheless, it has to be pointed out that a remarkable 
CR2-dependent enhancement of the antibody response which was found in mouse systems, 
has not been demonstrated in any human systems studied so far.  
 Concerning the function of CR1 on human B cells, results of studies carried out 
between 1980 and 1990 are much more controversial. In experiments using F(ab’)2 fragments 
of antibodies reacting with CR1, Daha et al. showed enhancement of non-specific Ig-
production when the cells were stimulated with a suboptimal dose of pokeweed mitogen 
(PWM) in the presence of T cells (97). Under these conditions monomeric C3b was 
ineffective. Later Weiss et al. found that CR1-specific monoclonal antibodies did not affect 
nonspecific B cell proliferation but elevated specific antibody production in the presence of T 
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cell-derived factors and suboptimal antigen dose (98). Tedder et al. however found no effect 
of CR1-specific antibodies in a similar experimental system (99). In contrast to these data, 
employing the natural ligand Berger and Fleisher had shown that C3b inhibited PWM-
induced Ig-production of human B cells (100). Similarly, Tsokos et al. also demonstrated the 
negative modulatory effect of C3b in conditions where the participation of other 
immunoregulatory cells could be excluded (101).  
Assuming that these controversial results are most probably due to the mixed cell 
populations and the different experimental conditions used by the authors, we decided to 
reinvestigate the role of CR1 in human B cell functions. We used highly purified B cells 
which were activated suboptimally via the BCR crosslinking in serum-free culture conditions, 
and for CR1 ligation C3b, the natural ligand was applied in a multimeric form (69). We 
demonstrated that clustering CR1 inhibited proliferation and Ca
2+-
response of human B cells, 
and proved that this inhibitory activity also occurs in the presence of the costimulatory 
cytokines IL-2 and IL-15. These results give evidence that human CR1 exerts an opposite 
effect to CR2, thus provides an additional level of regulation of humoral immunity (Fig.4). 
The therapeutic potential of CR1 inhibition was proven in a humanized SCID model, where 
selective co-cross-linking native DNA-specific BCR with the inhibitory CR1 suppressed B 
cell proliferation and autoantibody production (102). The inhibitory effect of CR1 in 
autoimmune patients (70) will be detailed in the next section.  
 
 
Human CR1 and CR2 are expressed differentially in various B cell subsets  
 
Based on the opposing functions of human CR1 and CR2 we assumed that their expression is 
different in various B cell subsets. Indeed, employing tonsil-derived B cells, where 
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complement receptor expression on germinal center (GC) B cells can be assessed in addition 
to the subpopulations present in blood, we have found that CR1 and CR2 expression changes 
oppositely during B cell differentiation. While CD19
+
, CD27
-
 naïve B cells upregulate their 
inhibitory CR1 during differentiation to CD19
+
, CD27
+
 memory cells, the expression of the 
activatory CR2 receptor is downregulated (70). Similarly to plasmablasts, both CR1 and CR2 
expression are markedly reduced on CD27
+
, CD10
+
, CD38
+
 GC B cells (our unpublished 
observation).  
We presume that the contrasting expression of CR1 and CR2 during human B cell 
differentiation have an essential role in the maintenance of peripheral B cell tolerance. The 
significantly decreased expression of CR1 - as well as the other main inhibitory receptor, 
FcγRIIb - on GC B cells may support the intensive proliferation of centroblasts and the 
differentiation of centrocytes into memory cells or plasmablasts. Alternatively, decreased 
appearance of both CR1 and CR2 on these B cell subsets can be the consequence of receptor 
internalization due to the continuous Ag screening and uptake of complement-tagged ligands. 
Later, however, the elevated expression of CR1 on memory B cells with parallel down-
regulation of the activatory CR2 may prevent the activation and differentiation of low-affinity, 
non-specific B cells into antibody secreting plasma cells a d restrict the immune response 
only to Ag-specific B cell clones, preventing autoimmunity (Fig.5). The important question 
still needs to be answered: how the ligands – namely C3b and C3dg - are generated and 
offered to B cells at the different stages? We think that it is a complex process, where antigen-
bound C3-fragments, local C3-production by different cells, C3-fragments present in ICs 
bound to FDCs, the presence or lack of regulatory proteins on the membrane of various cells, 
etc., might all play a role. 
 
Expression and function of CR1 and CR2 on human B cells in autoimmune conditions 
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In autoimmune conditions - including systemic lupus erythematosus (SLE) and rheumatoid 
arthritis (RA) - ICs containing the autoantigen, autoantibody and C3-fragments are not 
properly cleared from circulation. Hence their excessive binding to B cells together with the 
observed abnormal expression of FcγRIIb, CR1 and CR2 on the surface of human B cells may 
cause imbalance in the regulation of B cell functions, breaking self-tolerance and inducing 
autoreactivity.  
Although the reduced expression of CRs on erythrocytes as well as on leukocytes of 
autoimmune patients is known for long (103-105), the distribution of CR1 and CR2 on 
various B cell subsets in autoimmune conditions has been studied only recently (70, 106). Our 
group assessing CR1 and CR2 expression on different B lymphocyte subpopulations of 
healthy donors and SLE patients revealed that under physiological conditions, CD27
+
CD19
+
 
memory B cells express higher level of CR1 than CD27
-
CD19
+
 naïve cells. Its expression 
however is markedly decreased in both IgM
+
 and switched memory B cells of SLE patients. 
In contrast to CR1 however, no difference was found in the expression of CR2 between naïve 
and memory B cells of healthy individuals, and the reduced receptor expression affected all B 
cell populations of the patients (106). In the case of RA patients, although the expression of 
CR1 and CR2 was reduced on all tested B cell subpopulations, the change in the expression 
pattern during the differentiation of B lymphocytes was maintained. This finding points to a 
strict regulation of complement receptors in RA, which seems to be missing in other B cell-
mediated autoimmune diseases, such as SLE. 
Despite the reduced expression of CR1 in autoimmune patients, we have found that its 
inhibitory capacity is maintained and reduces both B cell proliferation and antibody secretion 
similarly to healthy individuals (70). Similar results were obtained investigating the function 
of CR2 on B cells of SLE patients, where despite the fact that B cells were found to express 
half as many surface CR2 as normal B lymphocytes, the Ca
2+ 
response and the percentage of 
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responding cells were significantly increased after co-ligation of BCR and CR2 (107). These 
observations suggest that down-regulation of IC-binding receptors on B cells may contribute 
to the induction of autoimmunity rather than affecting disease severity. Indeed, CR1 and CR2 
have been proven to play an essential role in the development of tolerance by presentation of 
self-antigens to autoreactive B cells at the immature stage (108). At this stage encounter of B 
cells with autoantigens leads to negative selection, thus defect in retention of self-antigens due 
to abnormal expression of CR1 and CR2 may cause impaired deletion and escape of anergic, 
self-reactive B cell clones to the periphery. This hypothesis is supported by the fact that 
CD21
low/-
 B lymphocytes have been found enriched in patients with autoimmune diseases 
(109) and these cells also fail to express CD35 (our unpublished results). CD21
low/-
 B cells are 
refractory to most stimulation and – instead of being eliminated – they remain in the blood of 
autoimmune patients where infections or abnormal clearance of ICs may create a favourable 
environment for their activation, leading to break of B cell tolerance and development of 
autoimmunity. 
Although the exact mechanism is still unresolved, these data suggest that concurrent 
changes in the expression and/or function of IC-binding receptors on B lymphocytes and other 
cell types may lead to aberrant B cell activation as well as Ag retention on B cells and FDCs, 
resulting in autoantibody secretion and induction of autoimmunity.  
 
 
CR3 (CD11b/CD18) and CR4 (CD11c/CD18)  
 
Complement receptor CR3 (CD11b/CD18, also known as Mac-1; αMβ2) and CR4 
(CD11c/CD18, also known as p150, 95; αXβ2) belong to the family of β2 integrins. These 
molecules are heterodimeric transmembrane glycoproteins consisting of a non-covalently 
coupled alpha and beta polypeptide chain, which have fundamental role in cell-cell, cell-
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extracellular matrix connections and locomotion. The 18 different α and 8 β-chains combine 
into 24 integrins that are classified based on their β chains (110, 111). In immunology, special 
attention is drawn to the leukocyte specific β2 family, which has four members; the well-
known LFA-1 (CD11a/CD18), the complement receptors CR3 (CD11b/CD18) and CR4 
(CD11c/CD18) and CD11d/CD18. 
Human CR3 and CR4 are closely related integrins; their α-chains share 87% identity 
in amino acid sequence in the extracellular part, and 56% in the short intracellular tail (112, 
113). The functional regions in human CD11b and CD11c are also shared with mouse CD11b 
(114). 
The common ligands of CR3 and CR4 include iC3b, the inactivated form of C3, 
fibrinogen and ICAM-1 (115-117). In both receptors the I-domain of the α-chain is 
responsible for ligand binding, although the β chain also plays an important role in 
maintaining the proper conformation for ligand binding (111, 118-123). By mapping the 
binding sites for various ligands Zhang et al. revealed that the fibrinogen binding site is 
different from the sequences which interact with iC3b (124). CR3 has an additional lectin type 
ligand binding site that can interact with the yeast product β-glucan and has an important role 
in effective tumour killing (125). Both CR3 and CR4 can bind LPS and several pathogens 
directly (117, 126-130). 
The tissue distribution of CR3 and CR4 is different in men and mice (Table 1). In 
humans CR3 and CR4 are mainly expressed on monocytes, macrophages, dendritic cells, 
PMNs and natural killer (NK) cells, and recently they have been detected on certain B 
lymphocyte populations as well (114, 131-133). In mice, expression of CD11c is far more 
limited, therefore it is used as a marker of mouse DCs.  
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Dissecting the functions of CR3 and CR4  
 
The similarities between CR3 and CR4 in structure and ligand specificity makes the study of 
their individual role extremely challenging. Furthermore, the competition between the ligands 
for CR3 and CR4, which exists in humans is lacking in mice due to the above mentioned 
differences in the receptors’ tissue distribution. Considering these facts it can be easily 
accepted that results obtained in mouse experiments cannot be simply translated to humans. 
Nevertheless, studies in human systems are also hindered by technical obstacles. Namely, 
when the function of CR3 and CR4 is investigated on phagocytes, both receptors are targeted 
at the same time, therefore the outcome of the experiment cannot be clearly associated only 
with one of them. These difficulties are further increased by the high intracellular pool and 
rapid recycling of integrins (134, 135). Due to these features, blocking one receptor with 
monoclonal antibodies to study the function of the other is challenging, because antibody 
covered integrins may translocate and reside inside the cell, while the unoccupied ones come 
to the surface, thereby lower the efficiency of receptor blocking. Finally, the possible 
proximity of CR3 and CR4 in the cell membrane may also be a source of false results caused 
by steric hindrance between adjacent receptors having bound antibodies or ligands. 
The best-known and most important function of CR3 is the phagocytosis of iC3b 
opsonized pathogens and apoptotic cells (136-139). The latter process is an immunologically 
silent mechanism, which is important in the induction of tolerance (51-53, 140). Based on the 
similarities between human CR3 and CR4 in structure, ligand specificity and expression, 
earlier it was hypothesized that CR4 is involved in similar processes as CR3 – most 
importantly in the phagocytosis of iC3b opsonized particles. The first indication of distinct 
roles for CR3 and CR4 came from the studies of Georgakopoulos et al., who showed that 
CD11c and CD11b are differentially involved in adhesion of human monocytes to fibrinogen 
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(141). Later Pliyev et al. proved that phagocytosis of iC3b opsonized particles by PMNs is 
dependent on CR1 and CR3, but not on CR4 (142).  
The function of CR4 has not been studied intensively so far most probably due to lack 
of specific monoclonal antibodies. Moreover, expression of CR4 is limited in mice, and in 
humans its expression level in some cell type is lower compared to CR3. Nevertheless, 
interesting studies performed in mice draw the attention to the importance of discriminating 
between CR3 and CR4. While the anti-inflammatory effect of CR3 is widely accepted, CR4 
seems to have rather a pro-inflammatory role (143, 144).  
CR3 and CR4 are accepted to play important roles in pathological conditions and it is 
known for long that inflammation can alter the expression level of these receptors. Due to 
mutations in the common β-chain, CR3 and CR4 are associated with leukocyte adhesion 
deficiency (LAD), an autosomal recessive disorder characterised by recurrent bacterial 
infections. Much attention is drawn to the role of CR3 in the pathogenesis of autoimmune 
diseases such as SLE and RA, and recently a single nucleotide polymorphism in the CD11b 
chain (rs1143679) has been identified as a risk factor in SLE (145). Although its function has 
not been described so far, CD11c was found to appear on the B cells of lupus prone mice and 
in human leukemic patients (146, 147). 
 
 
CR3 is the dominant receptor in opsonic phagocytosis by human DCs 
 
Our strong hypotheses is that due to an evolutionary thrift, CR3 and CR4 play different roles 
in human cell types. Therefore we set out to dissect their functions using human monocyte-
derived dendritic cells (MDCs), which express these two integrins in approximately equal 
amounts. Studying the interaction of MDCs with HIV-1 it was found that C3b-opsonized 
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virus particles caused up to ten-fold higher productive infection than the non-opsonized ones. 
This significantly higher infection rate could be reduced to background level by blocking the 
ligand binding site of CD11b (138). These results demonstrate that CR3 is the dominant 
receptor to mediate the uptake of iC3b opsonized HIV by MDCs, and this receptor directs 
opsonized HIV to cellular compartments which are favourable for productive infection. The 
prominent role of CR3 over CR4 was also demonstrated in the phagocytosis of iC3b 
opsonized yeast and bacterial particles by MDCs (148) (Fig.6). These results were confirmed 
by using siRNA; when downregulation of CD11b blocked the uptake of microbes by MDCs, 
while silencing CD11c had no effect at all. Although it has not been proven so far, one 
possible explanation for the differential function of CR3 and CR4 in these experiments is that 
the cytoskeletal association and mobility of the two receptors is different (113).  
 
 
CR3 and CR4 are differentially involved in adhesion of human DCs 
 
Mouse models revealed an important role for CR3 expressed by DCs in adhesion and 
cytokine production upon binding to fibrinogen (149, 150). These data, however, cannot be 
simply applied to the human system, where both CR3 and CR4 are expressed on several cell 
types which bind fibrinogen (151). Furthermore, integrin expression has been shown to be 
regulated differentially in the two species (152). In the study of Thacker et al. human MDCs 
were found to bind fibrinogen and secrete cytokines in a CD18-dependent manner, but the 
role of CR3 and CR4 could not be separated in these experiments (153). Georgakopoulos et 
al. showed that the contribution of these integrins to fibrinogen binding is dependent on the 
experimental conditions (141). We set out to dissect the role of CR3 and CR4 in adhesion, 
employing human monocyte derived macrophages (MDMs) and DCs and antibodies specific 
to the ligand binding site of the receptors. We found that CR4 ligation significantly decreases 
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the number of adhered cells and the force of adhesion in the case of both cell types, and 
inhibits macrophage spreading. These data show that strong adhesion to fibrinogen is mainly 
mediated by CR4, while the role of CR3 is negligible in this process (accepted in PLOS ONE, 
2016) (Fig.6). 
 
 
Conclusions, perspectives  
We have reviewed new aspects of complement mediated functions and exposed the 
importance of C3-derived fragments not only in bridging innate and adaptive immunity, but 
also in regulating immune responses.  
We are convinced that in addition to valuable data obtained in animal studies it is 
important to investigate human systems and understand the differences of complement 
functioning between men and mice. With the help of new methods to isolate and characterize 
various subpopulations of human T and B lymphocytes as well as macrophages and dendritic 
cells we shall be able to reveal the expression and role of various complement receptors at 
different developmental stages of these cells. Due to the complexity of signals integrated 
when B cells engage immune complexes bearing diverse complement fragments, the opposing 
role of CR1 and CR2 on human B cells needs further investigations, both in physiological and 
pathological conditions.  
Since several immunological processes take place in tissues where hepatocyte-derived 
complement proteins might not be available, locally produced complement components and 
their receptors are most likely involved in modulating cellular responses in situ. Recognition 
of further details of these processes will help better understand physiological and pathological 
processes.  
 
 
Acknowledgements 
Page 24 of 42Immunological Reviews: Submitted manuscript
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
25 
 
We thank József Prechl and István Kurucz for their helpful comments on the manuscript. 
This work was supported by the Hungarian National Science Fund (OTKA) grants K112011 
and K104838, and by the Hungarian Academy of Sciences.  
 
 
References 
 
1. Colten HR. Molecular biology of complement. BioEssays : news and reviews in molecular, 
cellular and developmental biology.1986;4:249-254. 
2. Erdei A, Fust G, Gergely J. The role of C3 in the immune response. Immunology 
today.1991;12:332-337. 
3. Andrews PA, Zhou W, Sacks SH. Tissue synthesis of complement as an immune regulator. 
Molecular medicine today.1995;1:202-207. 
4. Klos A, Wende E, Wareham KJ, Monk PN. International Union of Basic and Clinical 
Pharmacology. [corrected]. LXXXVII. Complement peptide C5a, C4a, and C3a receptors. 
Pharmacological reviews.2013;65:500-543. 
5. Sacks SH. Complement fragments C3a and C5a: the salt and pepper of the immune response. 
European journal of immunology.2010;40:668-670. 
6. Gros P, Milder FJ, Janssen BJ. Complement driven by conformational changes. Nature reviews 
Immunology.2008;8:48-58. 
7. Law SK, Levine RP. Interaction between the third complement protein and cell surface 
macromolecules. Proceedings of the National Academy of Sciences of the United States of 
America.1977;74:2701-2705. 
8. Helmy KY, et al. CRIg: a macrophage complement receptor required for phagocytosis of 
circulating pathogens. Cell.2006;124:915-927. 
9. Sim RB, Twose TM, Paterson DS, Sim E. The covalent-binding reaction of complement 
component C3. The Biochemical journal.1981;193:115-127. 
10. Gadjeva M, Dodds AW, Taniguchi-Sidle A, Willis AC, Isenman DE, Law SK. The covalent 
binding reaction of complement component C3. Journal of immunology.1998;161:985-990. 
11. Nelson RA, Jr. The immune-adherence phenomenon; an immunologically specific reaction 
between microorganisms and erythrocytes leading to enhanced phagocytosis. Science.1953;118:733-
737. 
12. Fearon DT. Identification of the membrane glycoprotein that is the C3b receptor of the 
human erythrocyte, polymorphonuclear leukocyte, B lymphocyte, and monocyte. The Journal of 
experimental medicine.1980;152:20-30. 
13. Bellinger-Kawahara C, Horwitz MA. Complement component C3 fixes selectively to the major 
outer membrane protein (MOMP) of Legionella pneumophila and mediates phagocytosis of 
liposome-MOMP complexes by human monocytes. The Journal of experimental 
medicine.1990;172:1201-1210. 
14. Puentes SM, Sacks DL, da Silva RP, Joiner KA. Complement binding by two developmental 
stages of Leishmania major promastigotes varying in expression of a surface lipophosphoglycan. The 
Journal of experimental medicine.1988;167:887-902. 
15. Schlesinger LS, Horwitz MA. Phenolic glycolipid-1 of Mycobacterium leprae binds 
complement component C3 in serum and mediates phagocytosis by human monocytes. The Journal 
of experimental medicine.1991;174:1031-1038. 
Page 25 of 42 Immunological Reviews: Submitted manuscript
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
26 
 
16. Mueller-Ortiz SL, Wanger AR, Norris SJ. Mycobacterial protein HbhA binds human 
complement component C3. Infection and immunity.2001;69:7501-7511. 
17. Karnchanaphanurach P, et al. C3b deposition on human erythrocytes induces the formation 
of a membrane skeleton-linked protein complex. The Journal of clinical investigation.2009;119:788-
801. 
18. Mold C, Nemerow GR, Bradt BM, Cooper NR. CR2 is a complement activator and the covalent 
binding site for C3 during alternative pathway activation by Raji cells. Journal of 
immunology.1988;140:1923-1929. 
19. Praz F, Karsenty G, Binet JL, Lesavre P. Complement alternative pathway activation by chronic 
lymphocytic leukemia cells: its role in their hepatosplenic localization. Blood.1984;63:463-467. 
20. Marquart HV, Gronbaek K, Christensen BE, Svehag SE, Leslie RG. Complement activation by 
malignant B cells from patients with chronic lymphocytic leukaemia (CLL). Clinical and experimental 
immunology.1995;102:575-581. 
21. Sissons JG, Oldstone MB, Schreiber RD. Antibody-independent activation of the alternative 
complement pathway by measles virus-infected cells. Proceedings of the National Academy of 
Sciences of the United States of America.1980;77:559-562. 
22. Ramos OF, Sarmay G, Klein E, Yefenof E, Gergely J. Complement-dependent cellular 
cytotoxicity: lymphoblastoid lines that activate complement component 3 (C3) and express C3 
receptors have increased sensitivity to lymphocyte-mediated lysis in the presence of fresh human 
serum. Proceedings of the National Academy of Sciences of the United States of 
America.1985;82:5470-5474. 
23. Erdei A, Fust G, Gyenes J, Fabry Z, Gergely J. C3b acceptors on human peripheral blood 
mononuclear cells; characterization and functional role. Immunology.1983;49:423-430. 
24. Marquart HV, Svehag SE, Leslie RG. CR2 is the primary acceptor site for C3 during alternative 
pathway activation of complement on human peripheral B lymphocytes. Journal of 
immunology.1994;153:307-315. 
25. Maison CM, Villiers CL, Colomb MG. Secretion, cleavage and binding of complement 
component C3 by the human monocytic cell line U937. The Biochemical journal.1989;261:407-413. 
26. Matsumoto M, Seya T. Homologous C3 deposition and homotypic cell adhesion in a human 
myeloid cell line, P39. European journal of immunology.1993;23:2270-2278. 
27. di Renzo L, et al. C3 molecules internalize and enhance the growth of Lewis lung carcinoma 
cells. Immunobiology.1999;200:92-105. 
28. Law SK, Dodds AW. The internal thioester and the covalent binding properties of the 
complement proteins C3 and C4. Protein science : a publication of the Protein Society.1997;6:263-
274. 
29. Erdei A, Kohler V, Schafer H, Burger R. Macrophage-bound C3 fragments as adhesion 
molecules modulate presentation of exogenous antigens. Immunobiology.1992;185:314-326. 
30. Olesen EH, Johnson AA, Damgaard G, Leslie RG. The requirement of localized, CR2-mediated, 
alternative pathway activation of complement for covalent deposition of C3 fragments on normal B 
cells. Immunology.1998;93:177-183. 
31. Bajtay Z, Kacani L, Erdei A, Dierich MP. HIV-1 induces human monocyte-derived macrophages 
to produce C3 and to fix C3 on their surface. Journal of leukocyte biology.1998;63:463-468. 
32. Kerekes K, Prechl J, Bajtay Z, Jozsi M, Erdei A. A further link between innate and adaptive 
immunity: C3 deposition on antigen-presenting cells enhances the proliferation of antigen-specific T 
cells. International immunology.1998;10:1923-1930. 
33. Kerekes K, Cooper PD, Prechl J, Jozsi M, Bajtay Z, Erdei A. Adjuvant effect of gamma-inulin is 
mediated by C3 fragments deposited on antigen-presenting cells. Journal of leukocyte 
biology.2001;69:69-74. 
34. Papp K, et al. B lymphocytes and macrophages release cell membrane deposited C3-
fragments on exosomes with T cell response-enhancing capacity. Molecular 
immunology.2008;45:2343-2351. 
Page 26 of 42Immunological Reviews: Submitted manuscript
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
27 
 
35. Nielsen CH, Pedersen ML, Marquart HV, Prodinger WM, Leslie RG. The role of complement 
receptors type 1 (CR1, CD35) and 2 (CR2, CD21) in promoting C3 fragment deposition and membrane 
attack complex formation on normal peripheral human B cells. European journal of 
immunology.2002;32:1359-1367. 
36. Sandor N, Pap D, Prechl J, Erdei A, Bajtay Z. A novel, complement-mediated way to enhance 
the interplay between macrophages, dendritic cells and T lymphocytes. Molecular 
immunology.2009;47:438-448. 
37. Erdei A, Benczur M, Fabry Z, Dierich MP, Gergely J. C3 cleaved by membrane proteases binds 
to C3b acceptors expressed on concanavalin A-stimulated human lymphocytes and enhances 
antibody-dependent cellular cytotoxicity. Scandinavian journal of immunology.1984;20:125-131. 
38. Torok K, Kremlitzka M, Sandor N, Toth EA, Bajtay Z, Erdei A. Human T cell derived, cell-bound 
complement iC3b is integrally involved in T cell activation. Immunology letters.2012;143:131-136. 
39. Barro CD, Villiers CL, Colomb MG. Covalent binding of non-proteolysed C3 to Jurkat T cells. 
Molecular immunology.1991;28:711-717. 
40. Ghebrehiwet B, Medicus RG, Muller-Eberhard HJ. Potentiation of antiboty-dependent cell-
mediated cytotoxicity by target cell-bound C3b. Journal of immunology.1979;123:1285-1288. 
41. Kemper C, Atkinson JP. T-cell regulation: with complements from innate immunity. Nature 
reviews Immunology.2007;7:9-18. 
42. Heeger PS, Kemper C. Novel roles of complement in T effector cell regulation. 
Immunobiology.2012;217:216-224. 
43. Zhou W, Peng Q, Li K, Sacks SH. Role of dendritic cell synthesis of complement in the 
allospecific T cell response. Molecular immunology.2007;44:57-63. 
44. van der Touw W, Cravedi P, Kwan WH, Paz-Artal E, Merad M, Heeger PS. Cutting edge: 
Receptors for C3a and C5a modulate stability of alloantigen-reactive induced regulatory T cells. 
Journal of immunology.2013;190:5921-5925. 
45. Raposo G, et al. B lymphocytes secrete antigen-presenting vesicles. The Journal of 
experimental medicine.1996;183:1161-1172. 
46. Reis ES, Barbuto JA, Isaac L. Complement components, regulators and receptors are 
produced by human monocyte-derived dendritic cells. Immunobiology.2007;212:151-157. 
47. van Kooten C, et al. Complement production and regulation by dendritic cells: molecular 
switches between tolerance and immunity. Molecular immunology.2008;45:4064-4072. 
48. Zhou W, Patel H, Li K, Peng Q, Villiers MB, Sacks SH. Macrophages from C3-deficient mice 
have impaired potency to stimulate alloreactive T cells. Blood.2006;107:2461-2469. 
49. Ghannam A, et al. Human C3 deficiency associated with impairments in dendritic cell 
differentiation, memory B cells, and regulatory T cells. Journal of immunology.2008;181:5158-5166. 
50. Ehirchiou D, Xiong Y, Xu G, Chen W, Shi Y, Zhang L. CD11b facilitates the development of 
peripheral tolerance by suppressing Th17 differentiation. The Journal of experimental 
medicine.2007;204:1519-1524. 
51. Schmidt J, Klempp C, Buchler MW, Marten A. Release of iC3b from apoptotic tumor cells 
induces tolerance by binding to immature dendritic cells in vitro and in vivo. Cancer immunology, 
immunotherapy : CII.2006;55:31-38. 
52. Skoberne M, et al. The apoptotic-cell receptor CR3, but not alphavbeta5, is a regulator of 
human dendritic-cell immunostimulatory function. Blood.2006;108:947-955. 
53. Sohn JH, Bora PS, Suk HJ, Molina H, Kaplan HJ, Bora NS. Tolerance is dependent on 
complement C3 fragment iC3b binding to antigen-presenting cells. Nature medicine.2003;9:206-212. 
54. Ezekowitz RA, Sim RB, Hill M, Gordon S. Local opsonization by secreted macrophage 
complement components. Role of receptors for complement in uptake of zymosan. The Journal of 
experimental medicine.1984;159:244-260. 
55. Baudino L, et al. C3 opsonization regulates endocytic handling of apoptotic cells resulting in 
enhanced T-cell responses to cargo-derived antigens. Proceedings of the National Academy of 
Sciences of the United States of America.2014;111:1503-1508. 
Page 27 of 42 Immunological Reviews: Submitted manuscript
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
28 
 
56. Strainic MG, et al. Locally produced complement fragments C5a and C3a provide both 
costimulatory and survival signals to naive CD4+ T cells. Immunity.2008;28:425-435. 
57. Cravedi P, Leventhal J, Lakhani P, Ward SC, Donovan MJ, Heeger PS. Immune cell-derived C3a 
and C5a costimulate human T cell alloimmunity. American journal of transplantation : official journal 
of the American Society of Transplantation and the American Society of Transplant 
Surgeons.2013;13:2530-2539. 
58. Li K, et al. Cyclic AMP plays a critical role in C3a-receptor-mediated regulation of dendritic 
cells in antigen uptake and T-cell stimulation. Blood.2008;112:5084-5094. 
59. Pantazis P, Kalyanaraman VS, Bing DH. Synthesis of the third component of complement (C3) 
by lectin-activated and HTLV-infected human T-cells. Molecular immunology.1990;27:283-289. 
60. Cardone J, et al. Complement regulator CD46 temporally regulates cytokine production by 
conventional and unconventional T cells. Nature immunology.2010;11:862-871. 
61. Kurtz CB, O'Toole E, Christensen SM, Weis JH. The murine complement receptor gene family. 
IV. Alternative splicing of Cr2 gene transcripts predicts two distinct gene products that share 
homologous domains with both human CR2 and CR1. Journal of immunology.1990;144:3581-3591. 
62. Jacobson AC, Weis JH. Comparative functional evolution of human and mouse CR1 and CR2. 
Journal of immunology.2008;181:2953-2959. 
63. Holers VM. Complement and its receptors: new insights into human disease. Annual review 
of immunology.2014;32:433-459. 
64. Carroll MC. The role of complement and complement receptors in induction and regulation 
of immunity. Annual review of immunology.1998;16:545-568. 
65. Sim RB, Malhotra V, Day AJ, Erdei A. Structure and specificity of complement receptors. 
Immunology letters.1987;14:183-190. 
66. Ogembo JG, et al. Human complement receptor type 1/CD35 is an Epstein-Barr Virus 
receptor. Cell reports.2013;3:371-385. 
67. Wagner C, et al. The complement receptor 1, CR1 (CD35), mediates inhibitory signals in 
human T-lymphocytes. Molecular immunology.2006;43:643-651. 
68. Torok K, Dezso B, Bencsik A, Uzonyi B, Erdei A. Complement receptor type 1 (CR1/CD35) 
expressed on activated human CD4+ T cells contributes to generation of regulatory T cells. 
Immunology letters.2015;164:117-124. 
69. Jozsi M, Prechl J, Bajtay Z, Erdei A. Complement receptor type 1 (CD35) mediates inhibitory 
signals in human B lymphocytes. Journal of immunology.2002;168:2782-2788. 
70. Kremlitzka M, Polgar A, Fulop L, Kiss E, Poor G, Erdei A. Complement receptor type 1 (CR1, 
CD35) is a potent inhibitor of B-cell functions in rheumatoid arthritis patients. International 
immunology.2013;25:25-33. 
71. Watry D, et al. Infection of human thymocytes by Epstein-Barr virus. The Journal of 
experimental medicine.1991;173:971-980. 
72. Tuveson DA, Ahearn JM, Matsumoto AK, Fearon DT. Molecular interactions of complement 
receptors on B lymphocytes: a CR1/CR2 complex distinct from the CR2/CD19 complex. The Journal of 
experimental medicine.1991;173:1083-1089. 
73. Carter RH, Fearon DT. CD19: lowering the threshold for antigen receptor stimulation of B 
lymphocytes. Science.1992;256:105-107. 
74. Tsokos GC, Thyphronitis G, Jack RM, Finkelman FD. Ligand-loaded but not free complement 
receptors for C3b/C4b and C3d co-cap with cross-linked B cell surface IgM and IgD. Journal of 
immunology.1988;141:1261-1266. 
75. Carter RH, Fearon DT. Polymeric C3dg primes human B lymphocytes for proliferation induced 
by anti-IgM. Journal of immunology.1989;143:1755-1760. 
76. Fingeroth JD, Weis JJ, Tedder TF, Strominger JL, Biro PA, Fearon DT. Epstein-Barr virus 
receptor of human B lymphocytes is the C3d receptor CR2. Proceedings of the National Academy of 
Sciences of the United States of America.1984;81:4510-4514. 
77. Aubry JP, Pochon S, Graber P, Jansen KU, Bonnefoy JY. CD21 is a ligand for CD23 and 
regulates IgE production. Nature.1992;358:505-507. 
Page 28 of 42Immunological Reviews: Submitted manuscript
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
29 
 
78. Pepys MB. Role of complement in induction of antibody production in vivo. Effect of cobra 
factor and other C3-reactive agents on thymus-dependent and thymus-independent antibody 
responses. The Journal of experimental medicine.1974;140:126-145. 
79. Ahearn JM, et al. Disruption of the Cr2 locus results in a reduction in B-1a cells and in an 
impaired B cell response to T-dependent antigen. Immunity.1996;4:251-262. 
80. Molina H, et al. Markedly impaired humoral immune response in mice deficient in 
complement receptors 1 and 2. Proceedings of the National Academy of Sciences of the United 
States of America.1996;93:3357-3361. 
81. Dempsey PW, Allison ME, Akkaraju S, Goodnow CC, Fearon DT. C3d of complement as a 
molecular adjuvant: bridging innate and acquired immunity. Science.1996;271:348-350. 
82. Melchers F, Erdei A, Schulz T, Dierich MP. Growth control of activated, synchronized murine B 
cells by the C3d fragment of human complement. Nature.1985;317:264-267. 
83. Erdei A, Melchers F, Schulz T, Dierich M. The action of human C3 in soluble or cross-linked 
form with resting and activated murine B lymphocytes. European journal of 
immunology.1985;15:184-188. 
84. Prechl J, et al. Targeting of influenza epitopes to murine CR1/CR2 using single-chain 
antibodies. Immunopharmacology.1999;42:159-165. 
85. Baiu DC, et al. Modulation of the humoral immune response by antibody-mediated antigen 
targeting to complement receptors and Fc receptors. Journal of immunology.1999;162:3125-3130. 
86. Arvieux J, Yssel H, Colomb MG. Antigen-bound C3b and C4b enhance antigen-presenting cell 
function in activation of human T-cell clones. Immunology.1988;65:229-235. 
87. Villiers MB, Villiers CL, Laharie AM, Marche PN. Amplification of the antibody response by 
C3b complexed to antigen through an ester link. Journal of immunology.1999;162:3647-3652. 
88. Prechl J, Erdei A. Immunomodulatory functions of murine CR1/2. 
Immunopharmacology.2000;49:117-124. 
89. Carroll MC. Complement and humoral immunity. Vaccine.2008;26 Suppl 8:I28-33. 
90. Carroll MC, Isenman DE. Regulation of humoral immunity by complement. 
Immunity.2012;37:199-207. 
91. Bohnsack JF, Cooper NR. CR2 ligands modulate human B cell activation. Journal of 
immunology.1988;141:2569-2576. 
92. Kuraya M, Nilsson B, Nilsson-Ekdahl K, Klein E. C3d-mediated negative and positive signals on 
the proliferation of human B cells separated from blood. Immunology letters.1990;26:51-58. 
93. Tsokos GC, Lambris JD, Finkelman FD, Anastassiou ED, June CH. Monovalent ligands of 
complement receptor 2 inhibit whereas polyvalent ligands enhance anti-Ig-induced human B cell 
intracytoplasmic free calcium concentration. Journal of immunology.1990;144:1640-1645. 
94. Nemerow GR, McNaughton ME, Cooper NR. Binding of monoclonal antibody to the Epstein 
Barr virus (EBV)/CR2 receptor induces activation and differentiation of human B lymphocytes. Journal 
of immunology.1985;135:3068-3073. 
95. Frade R, et al. Enhancement of human B cell proliferation by an antibody to the C3d receptor, 
the gp 140 molecule. European journal of immunology.1985;15:73-76. 
96. Luxembourg AT, Cooper NR. Modulation of signaling via the B cell antigen receptor by CD21, 
the receptor for C3dg and EBV. Journal of immunology.1994;153:4448-4457. 
97. Daha MR, Bloem AC, Ballieux RE. Immunoglobulin production by human peripheral 
lymphocytes induced by anti-C3 receptor antibodies. Journal of immunology.1984;132:1197-1201. 
98. Weiss L, Delfraissy JF, Vazquez A, Wallon C, Galanaud P, Kazatchkine MD. Monoclonal 
antibodies to the human C3b/C4b receptor (CR1) enhance specific B cell differentiation. Journal of 
immunology.1987;138:2988-2993. 
99. Tedder TF, Weis JJ, Clement LT, Fearon DT, Cooper MD. The role of receptors for complement 
in the induction of polyclonal B-cell proliferation and differentiation. Journal of clinical 
immunology.1986;6:65-73. 
100. Berger M, Fleisher TA. Native C3 does not bind to the C3b receptor (CR1) of human blood B 
lymphocytes or alter immunoglobulin synthesis. Journal of immunology.1983;130:1021-1023. 
Page 29 of 42 Immunological Reviews: Submitted manuscript
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
30 
 
101. Tsokos GC, Berger M, Balow JE. Modulation of human B cell immunoglobulin secretion by the 
C3b component of complement. Journal of immunology.1984;132:622-626. 
102. Kerekov NS, et al. Elimination of autoreactive B cells in humanized SCID mouse model of SLE. 
European journal of immunology.2011;41:3301-3311. 
103. Iida K, Mornaghi R, Nussenzweig V. Complement receptor (CR1) deficiency in erythrocytes 
from patients with systemic lupus erythematosus. The Journal of experimental 
medicine.1982;155:1427-1438. 
104. Wilson JG, Ratnoff WD, Schur PH, Fearon DT. Decreased expression of the C3b/C4b receptor 
(CR1) and the C3d receptor (CR2) on B lymphocytes and of CR1 on neutrophils of patients with 
systemic lupus erythematosus. Arthritis and rheumatism.1986;29:739-747. 
105. Illges H, Braun M, Peter HH, Melchers I. Reduced expression of the complement receptor 
type 2 (CR2, CD21) by synovial fluid B and T lymphocytes. Clinical and experimental 
immunology.2000;122:270-276. 
106. Isaak A, et al. Physiological up-regulation of inhibitory receptors Fc gamma RII and CR1 on 
memory B cells is lacking in SLE patients. International immunology.2008;20:185-192. 
107. Mitchell JP, Enyedy EJ, Nambiar MP, Lees A, Tsokos GC. Engagement of complement receptor 
2 on the surface of B cells from patients with systemic lupus erythematosus contributes to the 
increased responsiveness to antigen stimulation. Lupus.2002;11:299-303. 
108. Prodeus AP, et al. A critical role for complement in maintenance of self-tolerance. 
Immunity.1998;9:721-731. 
109. Wehr C, et al. A new CD21low B cell population in the peripheral blood of patients with SLE. 
Clinical immunology.2004;113:161-171. 
110. Tan SM. The leucocyte beta2 (CD18) integrins: the structure, functional regulation and 
signalling properties. Bioscience reports.2012;32:241-269. 
111. Hynes RO. Integrins: bidirectional, allosteric signaling machines. Cell.2002;110:673-687. 
112. Corbi AL, Kishimoto TK, Miller LJ, Springer TA. The human leukocyte adhesion glycoprotein 
Mac-1 (complement receptor type 3, CD11b) alpha subunit. Cloning, primary structure, and relation 
to the integrins, von Willebrand factor and factor B. The Journal of biological 
chemistry.1988;263:12403-12411. 
113. Ross GD, Reed W, Dalzell JG, Becker SE, Hogg N. Macrophage cytoskeleton association with 
CR3 and CR4 regulates receptor mobility and phagocytosis of iC3b-opsonized erythrocytes. Journal of 
leukocyte biology.1992;51:109-117. 
114. Miller LJ, Wiebe M, Springer TA. Purification and alpha subunit N-terminal sequences of 
human Mac-1 and p150,95 leukocyte adhesion proteins. Journal of immunology.1987;138:2381-
2383. 
115. Altieri DC, Agbanyo FR, Plescia J, Ginsberg MH, Edgington TS, Plow EF. A unique recognition 
site mediates the interaction of fibrinogen with the leukocyte integrin Mac-1 (CD11b/CD18). The 
Journal of biological chemistry.1990;265:12119-12122. 
116. Diamond MS, et al. ICAM-1 (CD54): a counter-receptor for Mac-1 (CD11b/CD18). The Journal 
of cell biology.1990;111:3129-3139. 
117. Van Strijp JA, Russell DG, Tuomanen E, Brown EJ, Wright SD. Ligand specificity of purified 
complement receptor type three (CD11b/CD18, alpha m beta 2, Mac-1). Indirect effects of an Arg-
Gly-Asp (RGD) sequence. Journal of immunology.1993;151:3324-3336. 
118. Ueda T, Rieu P, Brayer J, Arnaout MA. Identification of the complement iC3b binding site in 
the beta 2 integrin CR3 (CD11b/CD18). Proceedings of the National Academy of Sciences of the 
United States of America.1994;91:10680-10684. 
119. Liddington RC, Ginsberg MH. Integrin activation takes shape. The Journal of cell 
biology.2002;158:833-839. 
120. Gupta V, et al. The beta-tail domain (betaTD) regulates physiologic ligand binding to integrin 
CD11b/CD18. Blood.2007;109:3513-3520. 
121. Li Y, Zhang L. The fourth blade within the beta-propeller is involved specifically in C3bi 
recognition by integrin alpha M beta 2. The Journal of biological chemistry.2003;278:34395-34402. 
Page 30 of 42Immunological Reviews: Submitted manuscript
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
31 
 
122. Chen X, Xie C, Nishida N, Li Z, Walz T, Springer TA. Requirement of open headpiece 
conformation for activation of leukocyte integrin alphaXbeta2. Proceedings of the National Academy 
of Sciences of the United States of America.2010;107:14727-14732. 
123. Chen X, Yu Y, Mi LZ, Walz T, Springer TA. Molecular basis for complement recognition by 
integrin alphaXbeta2. Proceedings of the National Academy of Sciences of the United States of 
America.2012;109:4586-4591. 
124. Zhang L, Plow EF. Overlapping, but not identical, sites are involved in the recognition of C3bi, 
neutrophil inhibitory factor, and adhesive ligands by the alphaMbeta2 integrin. The Journal of 
biological chemistry.1996;271:18211-18216. 
125. Yan J, et al. Beta-glucan, a "specific" biologic response modifier that uses antibodies to target 
tumors for cytotoxic recognition by leukocyte complement receptor type 3 (CD11b/CD18). Journal of 
immunology.1999;163:3045-3052. 
126. Oliva CR, et al. The integrin Mac-1 (CR3) mediates internalization and directs Bacillus 
anthracis spores into professional phagocytes. Proceedings of the National Academy of Sciences of 
the United States of America.2008;105:1261-1266. 
127. Peyron P, Bordier C, N'Diaye EN, Maridonneau-Parini I. Nonopsonic phagocytosis of 
Mycobacterium kansasii by human neutrophils depends on cholesterol and is mediated by CR3 
associated with glycosylphosphatidylinositol-anchored proteins. Journal of 
immunology.2000;165:5186-5191. 
128. Wright SD, Levin SM, Jong MT, Chad Z, Kabbash LG. CR3 (CD11b/CD18) expresses one binding 
site for Arg-Gly-Asp-containing peptides and a second site for bacterial lipopolysaccharide. The 
Journal of experimental medicine.1989;169:175-183. 
129. Ingalls RR, Golenbock DT. CD11c/CD18, a transmembrane signaling receptor for 
lipopolysaccharide. The Journal of experimental medicine.1995;181:1473-1479. 
130. Zaffran Y, Zhang L, Ellner JJ. Role of CR4 in Mycobacterium tuberculosis-human macrophages 
binding and signal transduction in the absence of serum. Infection and immunity.1998;66:4541-4544. 
131. Prieto J, Eklund A, Patarroyo M. Regulated expression of integrins and other adhesion 
molecules during differentiation of monocytes into macrophages. Cellular 
immunology.1994;156:191-211. 
132. Beyer M, et al. The beta2 integrin CD11c distinguishes a subset of cytotoxic pulmonary T cells 
with potent antiviral effects in vitro and in vivo. Respiratory research.2005;6:70. 
133. Postigo AA, Corbi AL, Sanchez-Madrid F, de Landazuri MO. Regulated expression and function 
of CD11c/CD18 integrin on human B lymphocytes. Relation between attachment to fibrinogen and 
triggering of proliferation through CD11c/CD18. The Journal of experimental 
medicine.1991;174:1313-1322. 
134. Miller LJ, Bainton DF, Borregaard N, Springer TA. Stimulated mobilization of monocyte Mac-1 
and p150,95 adhesion proteins from an intracellular vesicular compartment to the cell surface. The 
Journal of clinical investigation.1987;80:535-544. 
135. Bretscher MS. Circulating integrins: alpha 5 beta 1, alpha 6 beta 4 and Mac-1, but not alpha 3 
beta 1, alpha 4 beta 1 or LFA-1. The EMBO journal.1992;11:405-410. 
136. Le Cabec V, Carreno S, Moisand A, Bordier C, Maridonneau-Parini I. Complement receptor 3 
(CD11b/CD18) mediates type I and type II phagocytosis during nonopsonic and opsonic phagocytosis, 
respectively. Journal of immunology.2002;169:2003-2009. 
137. Patel PC, Harrison RE. Membrane ruffles capture C3bi-opsonized particles in activated 
macrophages. Molecular biology of the cell.2008;19:4628-4639. 
138. Bajtay Z, Speth C, Erdei A, Dierich MP. Cutting edge: productive HIV-1 infection of dendritic 
cells via complement receptor type 3 (CR3, CD11b/CD18). Journal of immunology.2004;173:4775-
4778. 
139. Morelli AE, et al. Internalization of circulating apoptotic cells by splenic marginal zone 
dendritic cells: dependence on complement receptors and effect on cytokine production. 
Blood.2003;101:611-620. 
Page 31 of 42 Immunological Reviews: Submitted manuscript
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
32 
 
140. Verbovetski I, et al. Opsonization of apoptotic cells by autologous iC3b facilitates clearance 
by immature dendritic cells, down-regulates DR and CD86, and up-regulates CC chemokine receptor 
7. The Journal of experimental medicine.2002;196:1553-1561. 
141. Georgakopoulos T, Moss ST, Kanagasundaram V. Integrin CD11c contributes to monocyte 
adhesion with CD11b in a differential manner and requires Src family kinase activity. Molecular 
immunology.2008;45:3671-3681. 
142. Pliyev BK, Arefieva TI, Menshikov MY. Urokinase receptor (uPAR) regulates complement 
receptor 3 (CR3)-mediated neutrophil phagocytosis. Biochemical and biophysical research 
communications.2010;397:277-282. 
143. Castro FV, et al. CD11c provides an effective immunotarget for the generation of both CD4 
and CD8 T cell responses. European journal of immunology.2008;38:2263-2273. 
144. White AL, et al. Ligation of CD11c during vaccination promotes germinal centre induction and 
robust humoral responses without adjuvant. Immunology.2010;131:141-151. 
145. Han S, et al. Evaluation of imputation-based association in and around the integrin-alpha-M 
(ITGAM) gene and replication of robust association between a non-synonymous functional variant 
within ITGAM and systemic lupus erythematosus (SLE). Human molecular genetics.2009;18:1171-
1180. 
146. Rubtsov AV, et al. Toll-like receptor 7 (TLR7)-driven accumulation of a novel CD11c(+) B-cell 
population is important for the development of autoimmunity. Blood.2011;118:1305-1315. 
147. Nicolaou F, et al. CD11c gene expression in hairy cell leukemia is dependent upon activation 
of the proto-oncogenes ras and junD. Blood.2003;101:4033-4041. 
148. Sandor N, Kristof K, Parej K, Pap D, Erdei A, Bajtay Z. CR3 is the dominant phagocytotic 
complement receptor on human dendritic cells. Immunobiology.2013;218:652-663. 
149. Lu H, et al. LFA-1 is sufficient in mediating neutrophil emigration in Mac-1-deficient mice. The 
Journal of clinical investigation.1997;99:1340-1350. 
150. Flick MJ, et al. Leukocyte engagement of fibrin(ogen) via the integrin receptor 
alphaMbeta2/Mac-1 is critical for host inflammatory response in vivo. The Journal of clinical 
investigation.2004;113:1596-1606. 
151. Ugarova TP, Yakubenko VP. Recognition of fibrinogen by leukocyte integrins. Annals of the 
New York Academy of Sciences.2001;936:368-385. 
152. Singh-Jasuja H, et al. The mouse dendritic cell marker CD11c is down-regulated upon cell 
activation through Toll-like receptor triggering. Immunobiology.2013;218:28-39. 
153. Thacker RI, Retzinger GS. Adsorbed fibrinogen regulates the behavior of human dendritic 
cells in a CD18-dependent manner. Experimental and molecular pathology.2008;84:122-130. 
 
Page 32 of 42Immunological Reviews: Submitted manuscript
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
For Review Only
33 
 
Legend to Figures 
 
Fig.1. Generation of ligands for C3-receptors  
The complement cascade can be activated via three pathways: the classical, lectin-dependent 
and alternative route, and all these pathways lead to the activation of the central complement 
component, C3. The first cleavage products are C3a and C3b. The soluble C3a peptide may 
bind to G-protein coupled C3a receptors, while the larger activation fragment C3b has the 
capacity to bind covalently to C3b-acceptor sites (C3bA) present on the activating surface. 
Covalently fixed C3b is the main ligand of CR1 (CD35) and CRIg. C3b can be further 
processed to generate iC3b and C3d(g), which remain covalently attached to C3bA sites and 
are ready to interact with complement receptors CR3 (CD11b/CD18), CR4 (CD11c/CD18), 
CRIg and CR2 (CD21) expressed on several cell types. 
 
Fig.2. Enhancement of mouse T cell response by APC-bound and exosome deposited C3-
fragments 
Antigen presenting cells (APCs) - mouse macrophages and B cells bearing C3bA-bound C3b 
and iC3b are able to interact with CR1/2 expressing mouse T cells, resulting in augmented T 
cell response. Exosomes released by C3-fragment bearing APCs can exert a similar effect.  
 
Fig.3. Enhancement of human T cell response by locally generated C3-fragments fixed 
to DC 
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Activated human macrophages produce and activate C3, which results in covalent deposition 
of C3-fragments onto DCs present in their close vicinity („local opsonization”). DC-bound 
C3b and iC3b may then interact with CR1 and CR3 expressing T cells and increase the 
adherence between the APC and the responding T cell, leading to enhanced proliferation.  
 
Fig.4. Role of CR1 and CR2 in the regulation of B cell functions in men and mice 
Complement receptors CR1 (CD35) and CR2 (CD21) in human B cells are produced by two 
separate genes, Cr1 and Cr2. Occupancy of CR1 inhibits BCR induced proliferation, antibody 
and cytokine production both in physiological and autoimmune condition. In contrast to this, 
ligation of CR2 (CD21) which is in complex with CD19 and CD81, rather promotes B cell 
functions under certain experimental conditions. In mice CR1 and CR2 are encoded by a 
single gene, Cr2, and the cell membrane proteins CR1 and CR2 are generated by alternative 
splicing. On mouse B cells both CR1 and CR2 appear as a subunit of the co-receptor complex 
containing CD19 and CD81, and their ligation strongly enhance BCR dependent activation of 
murine B cells. The co-stimulatory effect of CR2 ligation on human B cells is considerable 
less pronounced than in mice. 
 
 
Fig.5. Differential expression of the inhibitory CR1 (CD35) and the activatory CR2 
(CD21) during human B cell differentiation 
CR1 expression on CD27
+
, CD10
-
, CD38
+
 human germinal center (GC) B cells is 
significantly diminished compared to CD27
-
 naive B cells, which may support the intensive 
proliferation of centroblasts and the differentiation of centrocytes into memory cells or 
plasmablasts. The elevated expression of the inhibitory CR1 on memory B cells parallel with 
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the down-regulation of the activatory CR2 may prevent the activation of low-affinity, non-
specific B cells and restrict the immune response to the Ag-specific B cell clones, preventing 
autoimmunity. 
 
Fig.6. CR3 and CR4 mediate different functions on human DCs 
Although iC3b and fibrinogen are common ligands for CR3 and CR4, these two integrins 
have different functions on human MDMs. The uptake of iC3b-opsonised particles is 
mediated mainly by CR3 (CD11b/CD18), in contrast to the adherence to fibrinogen, where 
CR4 (CD11c/CD18) plays a dominant role.  
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Table 1 Tissue distribution and function of C3-binding structures in men and mice 
Binding 
structure 
Cell 
type 
Function in humans Function in mice 
C3b 
Acceptor 
B cells 
serves as a site for formation of 
alternative pathway convertases on CR2 
enhancement of antigen presentation 
T cellsa enhancement of cytotoxicity  not expressed 
NK cells enhancement of cytotoxicity  no data 
Mf 
enhancement of T cell stimulation, 
inhibition of FcγR-mediated 
phagocytosis and ADCC 
enhancement of antigen presentation 
DC enhancement of T cell stimulation no data 
CR1 
(CD35) 
B cells 
inhibition of BCR dependent 
proliferation, plasmablast formation, Ab 
production and cytokine production, 
EBV infection,  
complement regulator 
CR1/2 
(CD21/
CD35) 
 
T cellsa 
inhibition of proliferation and cytokine 
synthesis, induction of Treg cells, 
complement regulator 
B cells 
BCR-dependent enhancement of 
antibody response 
BCR-independent enhancement of 
Ag-presentation 
Mo/mph 
phagocytosis, 
complement regulator 
FDC 
maintenance of  memory,  
complement regulator 
PMN 
phagocytosis, 
complement regulator 
T 
cellsa 
enhancement of cell-cell 
interactions 
RBC 
IC transport, 
complement regulator 
Mo/m
ph 
not expressed 
CR2 
(CD21, 
+ CD19 
+ CD81) 
B cells 
slight enhancement of proliferation and 
intracellular Ca2+ release 
binds EBV, CD23 and interferon 
FDC maintenance of  memory 
Ta cells 
enhancement of cell-cell interactions, 
EBV infection 
PMN not expressed 
Mo/mf not expressed 
 
FDC maintenance of memory 
PMN not expressed 
RBC not expressed 
CR3 
(CD11b/ 
CD18) 
B cells expressed on B-1 cell subpopulation regulation of T-cell activity in autoimmunity  
T cells 
regulation of cytotoxicity and 
proliferation 
upregulated upon virus infection on cytotoxic 
subpopulations 
Mo/mf phagocytosis, adhesion and migration phagocytosis, adhesion and migration 
DC phagocytosis, adhesion and migration phagocytosis, adhesion and migration 
PMN 
phagocytosis, degranulation, adhesion 
and migration 
phagocytosis, degranulation, adhesion and migration 
NK cells 
enhancement of cytotoxicity (β-glucan 
and iC3b dependent) 
enhancement of cytotoxicity (β-glucan and iC3b 
dependent) 
CR4 
(CD11c/ 
CD18) 
B cells
a
 adherence, proliferation–  not expressed 
T cells 
cell-mediated cytolysis by subset of CD8+ 
T-cells -  
not expressed 
Mo/mf adhesion, phagocytosis not expressed 
DC adhesion, phagocytosis cell specific marker (CD11c), phagocytosis 
PMN 
adhesion, enhancement of bactericidal 
activity 
not expressed 
NK cells no data not expressed 
 
a 
expressed on activated cells 
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C3b 
classical alternative lectin-dependent 
C3 
C3a 
C3d 
Covalently bound  
C3-fragments, 
ligands for C3-receptors 
CR1  
(CD35) 
CR2-complex  
(CD21, CD19, CD81) 
CR3  
(CD11b/ 
CD18) 
CR4  
(CD11c/ 
CD18) 
Receptors for covalently  
bound C3-fragments 
Complement activation 
Cleavage of C3 
C3aR 
# # # 
C3bA C3bA C3bA 
Figure 1 
CRIg  
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